Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 2
2013 4
2014 3
2015 5
2016 3
2017 2
2018 3
2019 2
2020 4
2021 9
2022 11
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.
Gerosa R, De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Saltalamacchia G, Torrisi R, Masci G, Miggiano C, Agustoni F, Pedrazzoli P, Santoro A, Zambelli A. Gerosa R, et al. Among authors: agustoni f. Crit Rev Oncol Hematol. 2024 Apr;196:104324. doi: 10.1016/j.critrevonc.2024.104324. Epub 2024 Mar 8. Crit Rev Oncol Hematol. 2024. PMID: 38462150 Free article. Review.
Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach.
Ceresoli GL, Rossi G, Agustoni F, Bonomi L, Borghetti P, Bulotta A, Casartelli C, Cerea G, Colonese F, Del Signore E, Finocchiaro G, Gianoncelli L, Grisanti S, Maiolani M, Pagni F, Proto C, Rijavec E, Vittimberga I, Arcangeli S, Filippi AR. Ceresoli GL, et al. Among authors: agustoni f. Crit Rev Oncol Hematol. 2024 Jan 31:104247. doi: 10.1016/j.critrevonc.2023.104247. Online ahead of print. Crit Rev Oncol Hematol. 2024. PMID: 38307393 Review.
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
Prelaj A, Ganzinelli M, Provenzano L, Mazzeo L, Viscardi G, Metro G, Galli G, Agustoni F, Corte CMD, Spagnoletti A, Giani C, Ferrara R, Proto C, Brambilla M, Dumitrascu AD, Inno A, Signorelli D, Pizzutilo EG, Brighenti M, Biello F, Bennati C, Toschi L, Russano M, Cortellini A, Catania C, Bertolini F, Berardi R, Cantini L, Pecci F, Macerelli M, Emili R, Bareggi C, Verderame F, Lugini A, Pisconti S, Buzzacchino F, Aieta M, Tartarone A, Spinelli G, Vita E, Grisanti S, Trovò F, Auletta P, Lorenzini D, Agnelli L, Sangaletti S, Mazzoni F, Calareso G, Ruggirello M, Greco GF, Vigorito R, Occhipinti M, Manglaviti S, Beninato T, Leporati R, Ambrosini P, Serino R, Silvestri C, Zito E, Pedrocchi ACL, Miskovic V, de Braud F, Pruneri G, Lo Russo G, Genova C, Vingiani A. Prelaj A, et al. Among authors: agustoni f. Clin Lung Cancer. 2024 Mar;25(2):190-195. doi: 10.1016/j.cllc.2023.12.012. Epub 2023 Dec 22. Clin Lung Cancer. 2024. PMID: 38262770 Free article.
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.
Passiglia F, Lucia Reale M, Lo Russo G, Pasello G, Minuti G, Bulotta A, Galetta D, Pelizzari G, Sini C, Bria E, Roca E, Pilotto S, Genova C, Metro G, Citarella F, Chiari R, Cortinovis D, Delmonte A, Russo A, Tiseo M, Cerea G, Carta A, Scotti V, Vavalà T, Brambilla M, Buffoni L, Buosi R, Catania C, Gori S, Grisanti S, Agustoni F, Garbo E, Malapelle U, Novello S. Passiglia F, et al. Among authors: agustoni f. Lung Cancer. 2024 Jan;187:107444. doi: 10.1016/j.lungcan.2023.107444. Epub 2023 Dec 15. Lung Cancer. 2024. PMID: 38157806 Free article.
Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease.
Bertuccio FR, Agustoni F, Galli G, Bortolotto C, Saddi J, Baietto G, Baio N, Montini S, Putignano P, D'Ambrosio G, Corsico AG, Pedrazzoli P, Stella GM. Bertuccio FR, et al. Among authors: agustoni f. Cancers (Basel). 2023 Dec 6;15(24):5731. doi: 10.3390/cancers15245731. Cancers (Basel). 2023. PMID: 38136277 Free PMC article. Review.
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group.
Catania C, Filippi AR, Sangalli C, Piperno G, Russano M, Greco C, Scotti V, Proto C, Bennati C, Di Pietro Paolo M, Platania A, Olmetto E, Agustoni F, Teodorani N, Agbaje V, Russo A. Catania C, et al. Among authors: agustoni f. Crit Rev Oncol Hematol. 2023 Oct;190:104108. doi: 10.1016/j.critrevonc.2023.104108. Epub 2023 Aug 24. Crit Rev Oncol Hematol. 2023. PMID: 37633350 Review.
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC).
Cavalieri S, Vitolo V, Barcellini A, Ronchi S, Facoetti A, Campo C, Klersy C, Molinelli S, Agustoni F, Ferretti VV, Silvestri A, Platania M, Del Vecchio M, Durante M, Helm A, Fournier C, Braud F, Pedrazzoli P, Orlandi E, Licitra L. Cavalieri S, et al. Among authors: agustoni f. Future Oncol. 2023 Jan;19(3):193-203. doi: 10.2217/fon-2022-0503. Epub 2023 Mar 28. Future Oncol. 2023. PMID: 36974574 Free article.
52 results